The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 82, Issue 6, 2011, Pages 671-673

  Maddison, Paul ^a   McConville, John ^b   Farrugia, Maria Elena ^c   Davies, Nicholas ^d   Rose, Michael ^e   Norwood, Fiona ^e   Jungbluth, Heinz ^f   Robb, Stephanie ^g   Hilton Jones, David ^h  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b ULSTER HOSPITAL   (United Kingdom)

^c SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^d QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

^f EVELINA LONDON CHILDREN S HOSPITAL   (United Kingdom)

^g GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^h JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN; MUSCLE SPECIFIC TYROSINE KINASE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; B LYMPHOCYTE; CHILD; CLINICAL ARTICLE; DISEASE DURATION; DISEASE EXACERBATION; DRUG TARGETING; EATON LAMBERT SYNDROME; FEMALE; FEVER; HUMAN; MALE; MEDICAL DECISION MAKING; MYASTHENIA GRAVIS; PLASMAPHERESIS; PRIORITY JOURNAL; REMISSION; RIGOR; SCHOOL CHILD; THYMECTOMY; TREATMENT OUTCOME; UNITED KINGDOM;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LAMBERT-EATON MYASTHENIC SYNDROME; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PROTEIN-TYROSINE KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; RETROSPECTIVE STUDIES;

EID: 79955754602     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2009.197632     Document Type: Article

References (22)

1. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006;6:859-66. (Pubitemid 44356635)
2. Looney RJ, Anolik J, Sanz I. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol 2004;16:180-5. (Pubitemid 38530483)
3. Zaja F, Russo D, Fuga G, et al. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 2000;55:1062-3.
4. Illa I, Diaz-Manera J, Rojas-Garcia R, et al. Sustained response to Rituximab in anti- AChR and anti-MuSK positive myasthenia gravis patients. J Neuroimmunol 2008;201-202:90-4.
5. Lebrun C, Bourg V, Tieulie N, et al. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol 2009;16:246-50.
6. Nelson RP, Pascuzzi RM, Kessler K, et al. Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review. J Clin Neuromusc Dis 2009;10:170-7.
7. Stieglbauer K, Topakian R, Schäffer V, et al. Rituximab for myasthenia gravis: three case reports and review of the literature. J Neurol Sci 2009;280:120-2.
8. Wylam ME, Anderson PM, Kuntz NL, et al. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J Pediatr 2003;143:674-7. (Pubitemid 37452801)
9. Gajra A, Vajpayee N, Grethlein SJ. Response of myasthenia gravis to Rituximab in a patient with non-Hodgkin lymphoma. Am J Hematol 2004;77:196-7. (Pubitemid 39281869)
10. Hain B, Jordan K, Deschauer M, et al. Successful treatment of MuSK antibody-positive myasthenia gravis with Rituximab. Muscle Nerve 2006;33:575-80.
11. Baek WS, Bashey A, Sheean GL. Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis. J Neurol Neurosurg Psychiatry 2007;78:771. (Pubitemid 46998860)
12. Thakre M, Inshasi J, Marashi M. Rituximab in refractory MuSK antibody myasthenia gravis. J Neurol 2007;254:968-9. (Pubitemid 47222302)
13. Díaz-Manera J, Rojas-García R, Gallardo E, et al. Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome. Nat Clin Pract Neurol 2007;3:405-10.
14. Evoli A, Bianchi MR, Riso R, et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann NY Acad Sci 2008;1132:76-83. (Pubitemid 351841355)
15. Kerkeni S, Marotte H, Miossec P. Improvement with Rituximab in a patient with both rheumatoid arthritis and myasthenia gravis. Muscle Nerve 2008;38:1343-5.
16. Strober J, Cowan MJ, Horn BN. Allogenic hematopoietic cell transplantation for refractory myasthenia gravis. Arch Neurol 2009;66:659-61.
17. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America. Neurology 2000;55:16-23. (Pubitemid 30460991)
18. Provan D, Butler T, Evangelista ML, et al. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica 2007;92:1695-8. (Pubitemid 350248251)
19. Renato GM. B cell depletion in early rheumatoid arthritis: a new concept in therapeutics. Ann N Y Acad Sci 2009;1173:729-35.
20. Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126:2304-11. (Pubitemid 37432373)
21. Maddison P, Lang B, Mills K, et al. Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. J Neurol Neurosurg Psychiatry 2001;70:212-17. (Pubitemid 32127859)
22. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the research on adverse drug events and reports (RADAR) project. Lancet Oncol 2009;10:816-24.